Analysis of a H1 ESC-derived MSCs showed these cells produced a factor (or factors) capable of robustly inducing NF-κB activity in MM cells in a manner resistant to bortezomib treatment (Figure 5A and 5B). The gene discussed is NFKB1; the disease is Miyoshi myopathy.